Home › Funds › GordonMD Global Investments LP › CRNX

GordonMD Global Investments LP position in CRNX

CRINETICS PHARMACEUTICALS IN

GordonMD Global Investments LP reported holding 126,985 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$4.8M, representing 2.30% of its reported portfolio and ranking #15 among its reported holdings. GordonMD Global Investments LP has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)126.98K sh
Reported value held$4.75M
Portfolio Weight2.30%
First reportedQ4 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How GordonMD Global Investments LP's CRNX position evolved

GordonMD Global Investments LP first disclosed a stake in CRNX in Q4 2025 at 224,135 shares (US$10.4M). Across 3 filings, GordonMD Global Investments LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 126,985 shares valued at US$4.8M. Notable position changes include a 43% trim in Q1 2026.

Quarter by quarter

QuarterSharesValueChange
Q4 2025 224.13K $10.43M New
Q1 2026 126.98K $4.61M Reduce
Q2 2026 126.98K $4.75M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CRNX and 13F data

CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 38 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CRNX

All CRNX fund holders →

FAQ

How long has GordonMD Global Investments LP held CRNX?

GordonMD Global Investments LP has disclosed CRNX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is GordonMD Global Investments LP's current position in CRNX?

As of Q2 2026, GordonMD Global Investments LP holds 126.98K shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $4.75M, representing 2.30% of its reported portfolio and ranking #15.

Has GordonMD Global Investments LP been buying or selling CRNX?

In the latest 13F filing (Q2 2026), GordonMD Global Investments LP held unchanged its position in CRNX.

Which other funds hold CRNX?

Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 38 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.